XXXX treatment in an adolescent with @entity162 .

@entity1 @entity1088 @entity162 @entity716 @entity1091 @entity2049
A 15 year-old adolescent @entity1 with a severe treatment refractory @entity162 type I, most recent episode @entity162 , severe with @entity716 features had previously required hospitalizations and treatment with @entity1091 and/or @entity2049 and high doses of standard neuroleptics without any response. A treatment with a combined @entity1088 - @entity1091 therapy was progressively started in a hospital setting ( @entity1088 300 mg/day; @entity1091 1350 mg/day). After 15 days a dramatic improvement in mood and @entity716 symptoms was evident. After four weeks there was 50% improvement on the BPRS (from 74 to 37). The mean CGAS score changed from 25 to 72. At the CGI-Severity of Illness subscale, a 57% decrease was evident; at the CGI-Global Improvement subscale there was a 75% increase. The only significant side effects were sedation and fatigue, but they were not so severe as to induce a reduction of dosage. The @entity1 was discharged from the hospital after three weeks and successfully returned to school with no modifications in treatment. After a nine-month treatment there was no reoccurrence of @entity716 or @entity162 . The implications of pharmacological therapy in treatment refractory @entity162 episodes with @entity716 features are discussed.
